SYCP2 and ovarian carcinoma: Building upon our previous findings that SYCP2 promotes homologous recombination (HR) by stimulating R-loop formation at sites of DNA damage [7], we sought to understand the observed correlation between SYCP2 expression levels and sensitivity to ABL1 inhibitors in ovarian cancer cells.